Azurrx biopharma, inc. (AZRX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities:
Net loss

-15,778

-15,177

-17,915

-16,295

-14,561

-13,533

-11,994

-12,557

-11,920

-11,096

-14,246

-14,310

-15,409

-14,591

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

55

63

67

65

64

61

59

56

53

49

47

45

44

44

0

0

0

Amortization

526

956

1,002

1,052

1,106

736

742

726

729

704

688

697

684

690

0

0

0

Non-cash lease expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Fair value adjustment, warrants

-

-

-

-

-

-

-

-

-

0

-455

-740

-2,398

-2,329

0

0

0

Fair value adjustment, contingent consideration

-

-

-

-

-

-210

-270

60

-30

-140

1,090

-60

200

300

0

0

0

Stock-based compensation

117

574

1,676

1,674

1,923

1,441

328

335

116

609

588

551

522

0

0

0

0

Common stock issued to settle accounts payable, amount

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Restricted stock granted to employees/directors

330

607

1,138

1,196

1,221

1,038

944

823

601

487

0

0

0

-

-

-

-

Restricted stock granted to consultants

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

Warrants issued to consultants

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Accrued interest on convertible debt

252

112

124

74

24

0

7

59

104

104

239

567

811

1,160

0

0

0

Accretion of debt discount

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Accreted interest on debt discount - warrants

-

-

-

-

-

97

0

0

0

-

-

-

-

883

0

0

0

Warrant modification

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Changes in assets and liabilities, net of effects of acquisition:
Other receivables

1,463

-749

-2,315

-2,374

-2,458

-2,187

-992

-73

156

3

84

-574

53

132

0

0

0

Prepaid expenses

-170

-85

-39

-73

-130

-243

7

92

-6

-43

564

-53

-170

-229

0

0

0

Right of use assets

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Deposits

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-1,768

-420

1,914

1,645

833

741

-920

186

-181

-233

-39

-324

665

805

0

0

0

Interest payable

-

-

-

-

-

-7

0

0

0

-

-

-

-

6

0

0

0

Net cash used in operating activities

-12,696

-14,033

-14,148

-12,660

-11,282

-10,869

-9,997

-8,624

-8,233

-7,184

-6,732

-6,665

-5,063

-4,534

0

0

0

Cash flows from investing activities:
Purchase of property and equipment

-9

0

218

222

233

250

16

19

28

0

31

21

12

12

0

0

0

Net cash used in investing activities

-15

-24

-274

-277

-289

-305

-48

-51

-61

-32

-31

-21

-12

-12

0

0

0

Cash flows from financing activities:
Proceeds issuances of common stock, net

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

Proceeds issuances of convertible debt, net

6,194

4,967

2,000

2,000

2,000

0

0

0

0

-

-

-

-

2,094

0

0

0

Received from stockholder in relation to warrant modification

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Repayments of convertible debt

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of notes payable

379

309

286

248

205

190

296

295

294

292

232

205

154

76

0

0

0

Net cash provided by financing activities

13,934

13,144

11,553

6,837

11,433

11,712

11,616

12,267

8,336

6,013

9,506

9,168

5,443

5,746

0

0

0

Increase (decrease) in cash

1,213

-921

-2,868

-6,101

-138

537

1,569

3,591

41

-1,203

2,742

2,480

368

1,199

0

0

0

Effect of exchange rate changes on cash

-5

-25

-8

-8

-22

3

-88

0

0

3

74

-7

-5

-7

0

0

0

Supplemental disclosures of cash flow information:
Cash paid for interest

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

Cash paid for income taxes

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

0

0

Cash paid for taxes

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

Non-cash investing and financing activities:
Convertible debt converted into common stock, Amount

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Conversion of preferred shares into common shares by Protea

-

-

-

-

-

-

-

-

-

-

-

-

-

3,479

0

0

0

Conversion of convertible debt into common shares

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Common stock issued Mayoly for patents, Amount

-1,740

0

3,040

3,040

3,040

1,300

0

0

0

-

-

-

-

-

-

-

-

Warrant modification related to convertible debt issuance

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-